# Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

> **NCT03908814** · PHASE1 · UNKNOWN · sponsor: **Dragonboat Biopharmaceutical Company Limited** · enrollment: 130 (estimated)

## Conditions studied

- Advanced Tumors

## Interventions

- **DRUG:** Whole Human Anti-PD-L1 Antibody Injection (LDP)

## Key facts

- **NCT ID:** NCT03908814
- **Lead sponsor:** Dragonboat Biopharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-27
- **Primary completion:** 2021-11-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2019-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03908814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03908814, "Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03908814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*